Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + donafenib + HAIC for unresectable biliary malignancies (phase II, single-arm)
ChiCTR2600120479Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and donafenib in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate. Started Mar 2026; status: recruiting.
02
Drugs
QL1706donafenib
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600120479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120479.